JP2015506376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506376A5 JP2015506376A5 JP2014555805A JP2014555805A JP2015506376A5 JP 2015506376 A5 JP2015506376 A5 JP 2015506376A5 JP 2014555805 A JP2014555805 A JP 2014555805A JP 2014555805 A JP2014555805 A JP 2014555805A JP 2015506376 A5 JP2015506376 A5 JP 2015506376A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- patient
- cancer
- administering
- cdk8
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 41
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 238000000034 method Methods 0.000 claims 20
- 201000011510 cancer Diseases 0.000 claims 10
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims 8
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims 8
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 6
- 150000003384 small molecules Chemical class 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 5
- 102100033145 Cyclin-dependent kinase 19 Human genes 0.000 claims 4
- 101000944345 Homo sapiens Cyclin-dependent kinase 19 Proteins 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102100024170 Cyclin-C Human genes 0.000 claims 3
- 239000012623 DNA damaging agent Substances 0.000 claims 3
- 101000980770 Homo sapiens Cyclin-C Proteins 0.000 claims 3
- 238000009098 adjuvant therapy Methods 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- YQGHJCYLMLPCCB-UHFFFAOYSA-N 2,4-diaminopyrimidin-5-ol Chemical compound NC1=NC=C(O)C(N)=N1 YQGHJCYLMLPCCB-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- -1 small molecule compound Chemical class 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010064390 Tumour invasion Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 230000009400 cancer invasion Effects 0.000 claims 1
- 230000002113 chemopreventative effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594023P | 2012-02-02 | 2012-02-02 | |
| US61/594,023 | 2012-02-02 | ||
| US201261673419P | 2012-07-19 | 2012-07-19 | |
| US61/673,419 | 2012-07-19 | ||
| PCT/US2013/024515 WO2013116786A1 (en) | 2012-02-02 | 2013-02-01 | Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506376A JP2015506376A (ja) | 2015-03-02 |
| JP2015506376A5 true JP2015506376A5 (enExample) | 2016-05-19 |
| JP6193268B2 JP6193268B2 (ja) | 2017-09-06 |
Family
ID=47716178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555805A Expired - Fee Related JP6193268B2 (ja) | 2012-02-02 | 2013-02-01 | Ｃｄｋ８／ｃｄｋ１９選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9321737B2 (enExample) |
| EP (2) | EP2809324B1 (enExample) |
| JP (1) | JP6193268B2 (enExample) |
| KR (1) | KR20150023223A (enExample) |
| CN (1) | CN104363913B (enExample) |
| AU (1) | AU2013214783B2 (enExample) |
| BR (1) | BR112014019052A8 (enExample) |
| CL (1) | CL2014002062A1 (enExample) |
| CO (1) | CO7151516A2 (enExample) |
| EA (2) | EA032429B1 (enExample) |
| GE (2) | GEP20186818B (enExample) |
| MY (1) | MY165446A (enExample) |
| PH (1) | PH12014501862A1 (enExample) |
| SG (1) | SG11201404596UA (enExample) |
| UA (1) | UA117342C2 (enExample) |
| WO (1) | WO2013116786A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2671194T3 (es) * | 2012-07-27 | 2018-06-05 | Biogen Ma Inc. | Compuestos que son agentes moduladores de S1P y/o agentes moduladores de ATX |
| BR112015003698A2 (pt) * | 2012-08-23 | 2017-07-04 | Hoffmann La Roche | compostos, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método para o tratamento de câncer |
| CA2890108C (en) | 2012-11-01 | 2021-03-02 | University Of South Carolina | Method for treating prostate cancer |
| EP2961409A1 (en) * | 2013-02-26 | 2016-01-06 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
| CN110183461A (zh) | 2013-12-24 | 2019-08-30 | 哈佛学院院长等 | 皮质抑素类似物及其合成和用途 |
| EP3205645B1 (en) * | 2014-04-18 | 2019-10-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CA2959762A1 (en) * | 2014-06-10 | 2016-02-04 | University Of South Carolina | Methods and compositions for treatment of her-positive cancers |
| US20210322651A1 (en) | 2014-12-18 | 2021-10-21 | Senex Biotechnology, Inc. | Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors |
| EP3294298A4 (en) | 2015-05-08 | 2018-10-17 | President and Fellows of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| EP3294418A4 (en) * | 2015-05-08 | 2019-01-02 | President and Fellows of Harvard College | Targeted selection of patients for treatment with cortistatin derivatives |
| WO2017004411A1 (en) | 2015-07-01 | 2017-01-05 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| EP3370720A1 (en) * | 2015-11-03 | 2018-09-12 | Lu License AB | Compounds for treatment of hypoproliferative disorders |
| WO2017091836A1 (en) * | 2015-11-25 | 2017-06-01 | University Of South Carolina | Enhancement of cytarabine activity by inhibiting cdk8/19 |
| WO2017164230A1 (ja) * | 2016-03-23 | 2017-09-28 | 国立大学法人 岡山大学 | リン酸化ｓａｒｍ１、抗体、ｓａｒｍ１リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、ｓａｒｍ１改変体及び使用 |
| US11285144B2 (en) | 2016-08-03 | 2022-03-29 | The Broad Institute, Inc. | Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity |
| US11578067B2 (en) * | 2017-01-30 | 2023-02-14 | Kyoto University | Compound, and method for producing regulatory T cells |
| WO2018151633A1 (ru) * | 2017-02-20 | 2018-08-23 | Закрытое Акционерное Общество "Биокад" | Способы получения производных 4-(((нафталин-2-ил)алкил)амино)хинозалин-6-карбонитрилов |
| WO2018156858A1 (en) * | 2017-02-23 | 2018-08-30 | University Of South Carolina | Use of cdk8/19 inhibitors for treatment of established colon cancer hepatic metastasis |
| JPWO2018159805A1 (ja) * | 2017-03-03 | 2020-01-09 | 国立大学法人京都大学 | 膵前駆細胞の製造方法 |
| US11013728B2 (en) | 2017-04-03 | 2021-05-25 | Kyoto Pharmaceutical Industries, Ltd. | Cyclin-dependent kinase 8 and/or 19 inhibitor |
| RU2641001C1 (ru) * | 2017-04-03 | 2018-01-15 | Закрытое Акционерное Общество "Биокад" | Соли 4-((2-(6-(4-метилпиперазин-1-карбонил)нафталин-2-ил)этил)амино)хиназолин-6-карбонитрила и фармацевтическая композиция |
| CN111278469A (zh) * | 2017-09-18 | 2020-06-12 | 陈扎克伯格生物中心公司 | 用于治疗三阴性乳腺癌的方法 |
| US11261184B2 (en) | 2017-10-02 | 2022-03-01 | Boehringer Ingelheim International Gmbh | [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors |
| RU2763347C2 (ru) * | 2018-03-01 | 2021-12-28 | Закрытое Акционерное Общество "Биокад" | Новые ингибиторы cdk8/19 |
| US12281080B2 (en) | 2018-08-21 | 2025-04-22 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
| US11014906B2 (en) | 2018-08-21 | 2021-05-25 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
| WO2020160537A1 (en) | 2019-02-01 | 2020-08-06 | University Of South Carolina | Bicyclic pyridine compositions and methods of using the same for cancer therapy |
| TW202237818A (zh) | 2020-11-20 | 2022-10-01 | 日商千紙鶴治療公司 | 成熟化劑 |
| CA3208794A1 (en) | 2021-02-09 | 2022-08-18 | Orizuru Therapeutics, Inc. | Maturation agent |
| WO2022204534A1 (en) * | 2021-03-25 | 2022-09-29 | University Of South Carolina | Cdk8/19 inhibitors for the treatment of cytokine storm |
| US20240400993A1 (en) | 2021-09-27 | 2024-12-05 | Kyoto University | Method for producing t cell |
| JPWO2023095802A1 (enExample) | 2021-11-24 | 2023-06-01 | ||
| WO2023095801A1 (ja) | 2021-11-24 | 2023-06-01 | レグセル株式会社 | ヒト誘導性制御性ｔ細胞およびその作製方法 |
| EP4497822A1 (en) | 2022-03-23 | 2025-01-29 | Kyoto University | Method for producing regulatory t cells |
| WO2023210578A1 (ja) | 2022-04-25 | 2023-11-02 | オリヅルセラピューティクス株式会社 | Ａｌｋ５阻害活性とｃｄｋ８／１９阻害活性とを有する成熟化剤 |
| CN119546748A (zh) | 2022-07-14 | 2025-02-28 | 千纸鹤治疗公司 | 细胞移植用纤维蛋白凝胶片 |
| TW202421780A (zh) | 2022-09-26 | 2024-06-01 | 國立大學法人京都大學 | T細胞的製造方法 |
| WO2024071039A1 (ja) | 2022-09-26 | 2024-04-04 | レグセル株式会社 | キメラ抗原受容体（ｃａｒ）を含む誘導性制御性ｔ細胞 |
| CN120676951A (zh) | 2023-02-08 | 2025-09-19 | 雷格细胞股份有限公司 | 用于治疗或预防天疱疮的药物组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| SI20324A (sl) * | 1997-10-27 | 2001-02-28 | Agouron Pharmaceuticals, Inc. | Substituirane 4-amino-tiazol-2-il spojine kot cdk inhibitorji |
| US6440959B1 (en) * | 1999-04-21 | 2002-08-27 | Hoffman-La Roche Inc. | Pyrazolobenzodiazepines |
| US20040180848A1 (en) | 2003-03-10 | 2004-09-16 | Fesik Stephen W. | Method of killing cancer cells |
| US20040180844A1 (en) | 2003-03-10 | 2004-09-16 | Fesik Stephen W. | Method of killing cancer cells |
| JP2006522794A (ja) * | 2003-04-10 | 2006-10-05 | ファイザー株式会社 | Ｎｒ２ｂ受容体拮抗物質としての二環系化合物 |
| US20080033000A1 (en) * | 2006-05-15 | 2008-02-07 | Senex Biotechnology, Inc. | Identification of CDKI pathway inhibitors |
| US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
-
2013
- 2013-02-01 GE GEAP201714080A patent/GEP20186818B/en unknown
- 2013-02-01 MY MYPI2014002269A patent/MY165446A/en unknown
- 2013-02-01 EP EP13704538.1A patent/EP2809324B1/en not_active Not-in-force
- 2013-02-01 WO PCT/US2013/024515 patent/WO2013116786A1/en not_active Ceased
- 2013-02-01 EP EP18186536.1A patent/EP3431087A1/en not_active Withdrawn
- 2013-02-01 BR BR112014019052A patent/BR112014019052A8/pt not_active Application Discontinuation
- 2013-02-01 SG SG11201404596UA patent/SG11201404596UA/en unknown
- 2013-02-01 AU AU2013214783A patent/AU2013214783B2/en not_active Ceased
- 2013-02-01 UA UAA201409643A patent/UA117342C2/uk unknown
- 2013-02-01 GE GEAP201313566A patent/GEP201706688B/en unknown
- 2013-02-01 US US13/757,682 patent/US9321737B2/en active Active
- 2013-02-01 JP JP2014555805A patent/JP6193268B2/ja not_active Expired - Fee Related
- 2013-02-01 CN CN201380017703.9A patent/CN104363913B/zh not_active Expired - Fee Related
- 2013-02-01 KR KR1020147024672A patent/KR20150023223A/ko not_active Ceased
- 2013-02-01 EA EA201791284A patent/EA032429B1/ru not_active IP Right Cessation
- 2013-02-01 EA EA201491399A patent/EA028595B1/ru not_active IP Right Cessation
-
2014
- 2014-08-01 CL CL2014002062A patent/CL2014002062A1/es unknown
- 2014-08-18 PH PH12014501862A patent/PH12014501862A1/en unknown
- 2014-08-30 CO CO14191136A patent/CO7151516A2/es unknown
-
2016
- 2016-03-09 US US15/065,083 patent/US10993945B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506376A5 (enExample) | ||
| JP2016508134A5 (enExample) | ||
| JP2014532647A5 (enExample) | ||
| JP2015523397A5 (enExample) | ||
| RU2014120792A (ru) | Способ лечения стромальных опухолей желудочно-кишечного тракта | |
| JP2016501221A5 (enExample) | ||
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| JP2013519645A5 (enExample) | ||
| RU2017105353A (ru) | Соединения | |
| JP2010525056A5 (enExample) | ||
| RU2018108589A (ru) | Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| JP2013506674A5 (enExample) | ||
| RU2017112747A (ru) | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции | |
| EA201500293A1 (ru) | Антихолинэргическая нейропротективная композиция и способы | |
| JP2016522254A5 (enExample) | ||
| JP2017531673A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| JP2019501879A5 (enExample) | ||
| RU2014139955A (ru) | Прокаспазная комбинированная терапия при глиобластоме | |
| JP2015522018A5 (enExample) | ||
| JP2013544892A5 (enExample) | ||
| JP2024535913A (ja) | Ｋｒａｓ変異を有するがん患者の治療 | |
| JP2011046708A5 (enExample) | ||
| RU2015101702A (ru) | Фармацевтически активные соединения |